Prolactin-related adverse risperidone

Similarly, risperidone caused extrapyramidal symptoms in fewer patients (24%) than haloperidol did (43%) in a two-phase study in patients with acute bipolar mania (phase I, 3 weeks, patients receiving either risperidone 1-6 mg/day, haloperidol 2-12 mg/day, or placebo (32). Plasma prolactin concentration was higher with risperidone (no data provided) prolactin-related adverse events included non-puerperal lactation, breast pain, dysmenorrhea, and reduced libido or sexual dysfunction these effects occurred in six patients on risperidone (4%) and in two on haloperidol (1.3%). 

In one study, the prevalence of hyperprolactinemia among women taking risperidone was 88% (n = 42) versus 48% (n = 105) in those taking conventional antipsychotic drugs 48% of these women of reproductive age taking risperidone had abnormal menstrual cycles (137). In the whole sample (147 women and 255 men) there were trends towards low concentrations of reproductive hormones associated with rises in prolactin patients taking concomitant medications known to increase prolactin had been excluded. Raised prolactin concentrations were also observed in 13 (9 women and 4 men) of 20 patients (13 women and 7 men mean age 36 years) (138). In premenopausal women there was a good correlation between prolactin concentrations and age, but there was no clear correlation between duration of treatment, dose, prolactin concentration, and prolactin-related adverse effects. 

In the second study, which lasted 2 years, long-acting injectable risperidone (n = 50) was compared with oral risperidone (n = 47) and haloperidol (n = 47) [130. Prolactin-related adverse events occurred in four of those who received injectable risperidone galactorrhea in one amenorrhea... 

In 50 patients with newly diagnosed schizophrenia (mean age 25 years) who were treated with injectable risperidone 25-50 mg every 2 weeks for 2 years [132 ], prolactin concentrations increased in 18 patients, four of whom reported possible prolactin-related adverse events (amenorrhea in one galactorrhea in one amenorrhea and galactorrhea in one amenorrhea and delayed menses in one). Mean increase in body mass index was 4.8 kg/m 10 subjects required anticholinergic medication, and one developed persistent dyskinesia. 

Observational Studies A 12-week, open-label study of 58 patients receiving risperidone randomised to continue with risperidone or switch to paliperidone ER found a side-effect profile for paliperidone ER similar to that of risperidone, including metabolic problems and prolactin-related adverse events [18 ]. 

The relation of prolactin concentrations and certain adverse events has been explored by using data from two large randomized, double-blind studies (n = 2725 813 women, 1912 men) (1018). Both risperidone and haloperidol produced dose-related increases in plasma prolactin concentrations in men and women, but they were not correlated with adverse events such as amenorrhea, galactorrhea, or reduced libido in women or with erectile dysfunction, ejaculatory dysfunction, gynecomastia, or reduced libido in men. Nevertheless, in five patients risperidone (1-8 mg/day) caused amenorrhea in association with raised serum prolactin concentrations (mean 122 ng/ml, range 61-230 ng/ml reference range 2.7-20 ng/ml) (1019). 

---